Screener
Allogene Therapeutics ALLO Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares were issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value: 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 244,816,413 and 229,413,523 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 245 | 229 |
| Additional paid-in capital | 2,332,129 | 2,302,753 |
| Accumulated deficit | (2,053,316) | (2,010,709) |
| Accumulated other comprehensive income (loss) | (183) | 269 |
| Total stockholders’ equity | 278,875 | 292,542 |
| Total liabilities and stockholders’ equity | $395,958 | $415,905 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's total liabilities & equity?
- Allogene Therapeutics (ALLO) reported total liabilities & equity of $395.96M in Q1 2026.
- How has Allogene Therapeutics's total liabilities & equity changed year-over-year?
- Allogene Therapeutics's total liabilities & equity decreased by 22.1% year-over-year, from $507.98M to $395.96M.
- What is the long-term trend for Allogene Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Allogene Therapeutics's total liabilities & equity has grown at a -19.5% compound annual growth rate (CAGR), from $1.23B to $415.91M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Allogene Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude